---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-017164"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2026-01-21T23:59:59+00:00"
generated_at: "2026-05-16T09:21:14.598561+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IO Biotech to explore strategic alternatives including merger, sale, or liquidation

## Summary
- Company to evaluate merger, business combination, sale of assets, or liquidation and dissolution.
- Further reduction-in-force and cost-cutting measures are also under consideration.
- No timetable for the process; no assurance any transaction will occur.
- IO Biotech (Nasdaq: IOBT) is a clinical-stage cancer vaccine developer.

## SEC filing metadata
- accession: 0001193125-26-017164
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2026-01-21T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312526017164/0001193125-26-017164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312526017164/d26457d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-017164
- JSON: https://secwatch.observer/filing/0001193125-26-017164.json
- Plain text: https://secwatch.observer/filing/0001193125-26-017164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.